X-Plus 4 Brain Photobiomodulation Device Experience Advanced Brain Wellness with the X-Plus 3 Brain Photobiomodulation Device The Vielight X-Plus stimulates the thymus gland and nasal vasculature with light energy to augment the body’s innate immune system and reduces inflammation. The Vielight RX-Plus produced statistically significant results in an n=295 clinical trial for Covid-19 recovery and received Health Canada approval. Target structure Benefit Thymus gland Improved immunity. Nasal vascular area Improved immunity and systemic fitness. Specifications Power Density | Irradiance 50 mW/cm² (1) : Body Module LED25 mW/cm² (1) : Head Module LED10 mW/cm² (1) : Intranasal LED (633nm) LED Power 1000 mW per module Targeted Areas Cerebellum, Occipital lobe, Thymus gland, Nasal vasculature Head Size Suitability Minimum age: 5 years old Medical Grade Certification ISO13485 and MDSAP Safety Certification TÜV Rheinland Warranty 24 months Satisfaction Guarantee We have an 80% refund policy, valid for 3 months from the time of purchase Warranty: One-year manufacturer’s warranty. Shipping: We have shipping depots located in California (United States), Ontario (Canada) and Perth (Australia). We ship internationally to Europe. Shipping times may vary between 2-14 business days. Returns: Your Vielight product purchases are backed by a 6-months no-question-asked return policy which entitles you to receive 80% of your purchase price back within the first 6 months from the date of the purchase. Important Note: Our customer support, satisfaction guarantee and product warranty will not apply to devices sold through unauthorized channels, such as Amazon and eBay. More Info: Please note that this product comes with an intranasal applicator. Health Canada Approval Vielight Inc. Receives Health Canada Approval for Treatment of Covid-19 with Near Infrared Device Technology Approval from Canada’s Top Federal Health Agency Followed Positive Clinical Trial Results We are honored to announce that the Vielight RX Plus device has received medical device approval from Health Canada! We conducted an n=295 clinical trial for Covid-19 recovery for which the results were statistically significant. This represents two historic milestones: The RX Plus is the first medical device to be approved for the treatment of COVID-19 infection. The RX Plus is the first non-invasive photobiomodulation (PBM) technology to be approved for a major indication. The RX Plus combines our patented red and near-infrared light technology to accelerate the recovery of adults with COVID-19. We designed it to be non-invasive, portable, and lightweight to meet the needs of those who prefer to recover at home or on-the-go. Clinical trial results can be found here: https://medrxiv.org/cgi/content/short/2022.06.16.22276503v1 Information on the Health Canada license can be found here: https://health-products.canada.ca/mdall-limh/information?companyId=136815&lang=eng In the past, we worked with Harvard Medical School on anti-pathogenic research using blue light energy: https://www.vielight.com/research/#anti-viral The effects of Photobiomodulation on Immunity. (The text below is based on an article from Liebert A, Bicknell B, Markman W, Kiat H. A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19. Aging Dis. 2020 Dec 1;11(6):1352-1362. doi: 10.14336/AD.2020.0901. PMID: 33269093; PMCID: PMC7673843) PBM appears to exert pluripotent effects in the modulation of inflammation and immunity [1]. Many studies have demonstrated that PBM modulates inflammation by reducing the pro-inflammatory cytokines (such as IL-1β, IL-6, IL-8, TNF-α) and other inflammatory markers released from activated inflammatory cells, while increasing the anti-inflammatory cytokines (IL-10) [2]. The immuno-modulatory effect of PBM on cytokines regulation and the complement cascade occurs via the POMC pathway, involving regulation of the hypothalamic pituitary axis through the direct modulation of the POMC/melanocortin signalling pathway including a-MSH, a potent anti-inflammatory molecule. The POMC pathway is regulated by PBM [3], which in turn modulates both ACTH and β-opioid, as well as, interestingly, ACE activity [4]. One of the central effects of PBM on the immune response is via the modulation of neutrophil function [5] by balancing neutrophil numbers, improving neutrophil efficiency and modulating the neutrophil extracellular trap formation [6]. Reducing over-accumulation of neutrophils is a major mechanism for the effect of PBM in reducing acute lung inflammation [7]. This is crucial in preventing the cytokine storm cascade in autoimmune diseases. PBM also modulates the ratio of M1 and M2 macrophage phenotypes, reducing pro-inflammatory cytokines and chemokines and increasing anti-inflammatory cytokines and thus balance the inflammatory process [8]. These inflammatory changes facilitated by PBM have profound effects on many body processes. For example, PBM therapy has been shown to modulate peripheral blood mononuclear cells and CD4+ cells to reduce inflammatory effects in multiple sclerosis patients and healthy adults by increasing IL-10 and reducing IFN-γ [9, 10]. PBM reduces the number of inflammatory cells, pro-inflammatory cytokines as well as fibrotic tissue in a mouse model of lung fibrosis [11]. Acute lung inflammation in rats is reduced with PBM to reduce oedema, neutrophil influx and TNF-α, while reducing IL-10 in rats [12]. In an experimental model of induced acute peritonitis in rats, Yu and co-workers [13] showed PBM resulted in lymphocyte proliferation and enhanced lymphocyte ATP synthesis compared to controls, and the 60-day survival rate of the PBM group was double that of the control group (p
